Murphy Capital Management Inc. acquired a new stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,870 shares of the medical equipment provider’s stock, valued at approximately $245,000.

Other hedge funds have also made changes to their positions in the company. Flinton Capital Management LLC grew its holdings in shares of Zimmer Biomet by 8.0% in the second quarter. Flinton Capital Management LLC now owns 12,444 shares of the medical equipment provider’s stock valued at $1,387,000 after purchasing an additional 918 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Zimmer Biomet by 0.8% in the second quarter. Dimensional Fund Advisors LP now owns 957,471 shares of the medical equipment provider’s stock valued at $106,700,000 after purchasing an additional 7,733 shares in the last quarter. Legal & General Group Plc lifted its stake in Zimmer Biomet by 2.3% in the second quarter. Legal & General Group Plc now owns 983,726 shares of the medical equipment provider’s stock worth $109,634,000 after acquiring an additional 21,825 shares during the last quarter. HPM Partners LLC lifted its stake in Zimmer Biomet by 29.3% in the second quarter. HPM Partners LLC now owns 13,241 shares of the medical equipment provider’s stock worth $1,476,000 after acquiring an additional 3,001 shares during the last quarter. Finally, Capital Fund Management S.A. lifted its stake in Zimmer Biomet by 416.6% in the second quarter. Capital Fund Management S.A. now owns 87,724 shares of the medical equipment provider’s stock worth $9,776,000 after acquiring an additional 70,742 shares during the last quarter. Hedge funds and other institutional investors own 87.18% of the company’s stock.

A number of research analysts recently issued reports on ZBH shares. Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Monday, August 27th. Canaccord Genuity lifted their price target on shares of Zimmer Biomet from $122.00 to $125.00 and gave the stock a “hold” rating in a research note on Monday, July 30th. Citigroup lifted their price target on shares of Zimmer Biomet from $117.00 to $128.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 31st. Robert W. Baird lifted their price target on shares of Zimmer Biomet from $121.00 to $132.00 and gave the stock a “neutral” rating in a research note on Monday, July 30th. Finally, Cantor Fitzgerald lifted their price target on shares of Zimmer Biomet from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 30th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $135.55.

Shares of NYSE:ZBH opened at $123.30 on Friday. The company has a market cap of $26.75 billion, a PE ratio of 15.35, a P/E/G ratio of 2.41 and a beta of 1.08. The company has a quick ratio of 1.25, a current ratio of 2.41 and a debt-to-equity ratio of 0.78. Zimmer Biomet Holdings Inc has a twelve month low of $104.28 and a twelve month high of $134.55.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.04. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.99 billion. Zimmer Biomet had a net margin of 21.67% and a return on equity of 13.53%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.08 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings Inc will post 7.66 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 31st. Stockholders of record on Friday, September 28th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.78%. Zimmer Biomet’s dividend payout ratio is presently 11.96%.

In other news, VP Tony W. Collins sold 2,778 shares of the business’s stock in a transaction that occurred on Tuesday, July 31st. The shares were sold at an average price of $125.77, for a total transaction of $349,389.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bryan C. Hanson acquired 410 shares of Zimmer Biomet stock in a transaction dated Friday, August 31st. The shares were bought at an average price of $123.03 per share, with a total value of $50,442.30. Following the transaction, the chief executive officer now directly owns 25,487 shares in the company, valued at approximately $3,135,665.61. The disclosure for this purchase can be found here. 0.71% of the stock is currently owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: Closed-End Mutual Funds (CEFs)

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.